Insmed CFO Sara Bonstein to step down October 30; company reaffirms full-year 2026 guidance

INSMED Inc

CFO Sara Bonstein will separate from Insmed effective October 30, 2026, and will stay through the Q3 2026 results and the October 29 earnings call.
Insmed said the transition is not related to any disagreement on accounting practices, financial statements, internal controls or operations.
Insmed reaffirmed 2026 guidance: BRINSUPRI revenue of $1.25B-$1.40B and ARIKAYCE revenue of $450M-$470M.
CEO Will Lewis said Insmed raised more than $4.2 billion in capital during Bonstein's nearly seven years as CFO; a search firm is aiding the successor search.
Q3 2026 financial results will be released October 29, 2026, with a conference call at 8:00 a.m. ET.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.